Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.71 |
| ▸ | HTR3B | O95264 | 4/20 | 0.71 |
| ▸ | HTR3A | P46098 | 4/20 | 0.71 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.71 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886692 | 1.00 | CHRNA7 (0.71) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2228216 | 0.86 | CHRNA7 (0.71) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2228213 | 0.86 | CHRNA7 (0.71) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2231092 | 0.86 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17888308 | 0.86 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2231088 | 0.86 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13496962 | 0.84 | CHRNA7 (0.76) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL10436185 | 0.83 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4214952 | 0.83 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL6208420 | 0.83 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | CHRNA7 4162/4885HTR3E 980/4885HTR3B 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.